Overview

Metrics

Content

Purchase

EXECUTIVE SUMMARY
Figure E.1: Effectiveness Ratings of Pharmacoeconomics/Health Outcomes Groups 12
Figure E.2: Pharmacoeconomics/Health Outcomes 2006 Department Budgets 19
Figure E.3: Allocation of Pharmacoeconomics/Health Outcomes Departments’ 20

Time Resources
Figure E.4: Allocation of Pharmacoeconomics/Health Outcomes Departments’ 21

Monetary Resources
Figure E.5: Preclinical Maximum/Minimum Brand-Level Spending 22
Figure E.6: Phase I Maximum/Minimum Brand-Level Spending 23
Figure E.7: Phase II Maximum/Minimum Brand-Level Spending 23

COMPANY 1
Figure 1.1: Company 1: Background 30
Figure 1.2: Company 1: Structure Details 30
Figure 1.3: Company 1: Pharmacoeconomics Staffing 31
Figure 1.4: Company 1: Budget for 2006 33
Figure 1.5: Company 1: Pharmacoeconomics/Health Outcomes Funding 34
Figure 1.6: Company 1: Outsourcing 34
Figure 1.7: Company 1: Brand-Level Phase-to-Phase Minimum Spending 35
Figure 1.8: Company 1: Brand-Level Phase-to-Phase Maximum Spending 36
Figure 1.9: Company 1: Time Resource Allocation 38
Figure 1.10: Company 1: Monetary Resource Allocation 39
Figure 1.11: Company 1: Performance Rating/Top Challenges 41

COMPANY 2
Figure 2.1: Company 2: Background 44
Figure 2.2: Company 2: Structure Details 44
Figure 2.3: Company 2: Structure 45
Figure 2.4: Company 2: Department Staffing 46
Figure 2.5: Company 2: Budget for 2006 48
Figure 2.6: Company 2: Pharmacoeconomics/Health Outcomes Funding 48
Figure 2.7: Company 2: Outsourcing 49
Figure 2.8: Company 2: Brand-Level Phase-to-Phase Minimum Spending 50
Figure 2.9: Company 2: Brand-Level Phase-to-Phase Maximum Spending 51
Figure 2.10: Company 2: Time Resource Allocation 52
Figure 2.11: Company 2: Monetary Resource Allocation 53
Figure 2.12: Company 2: Performance Rating/Top Challenges 55

COMPANY 3
Figure 3.1: Company 3: Background 58
Figure 3.2: Company 3: Structure Details 58
Figure 3.3: Company 3: Structure 59
Figure 3.4: Company 3: Department Staffing 60
Figure 3.5: Company 3: Budget for 2006 63
Figure 3.6: Company 3: Pharmacoeconomics/Health Outcomes Funding 64
Figure 3.7: Company 3: Outsourcing 65
Figure 3.8: Company 3: Brand-Level Phase-to-Phase Minimum Spending 66
Figure 3.9: Company 3: Brand-Level Phase-to-Phase Maximum Spending 67
Figure 3.10: Company 3: Time Resource Allocation 69
Figure 3.11: Company 3: Monetary Resource Allocation 70
Figure 3.12: Company 3: Performance Rating/Top Challenges 71

COMPANY 4
Figure 4.1: Company 4: Background 76
Figure 4.2: Company 4: Structure Details 76
Figure 4.3: Company 4: Department Structure 77
Figure 4.4: Company 4: Department Staffing 77
Figure 4.5: Company 4: Budget for 2006 80
Figure 4.6: Company 4: Pharmacoeconomics/Health Outcomes Funding 80
Figure 4.7: Company 4: Outsourcing 81
Figure 4.8: Company 4: Brand-Level Phase-to-Phase Minimum Spending 82
Figure 4.9: Company 4: Brand-Level Phase-to-Phase Maximum Spending 82
Figure 4.10: Company 4: Time Resource Allocation 84
Figure 4.11: Company 4: Monetary Resource Allocation 85
Figure 4.12: Company 4: Performance Rating 86

COMPANY 5
Figure 5.1: Company 5: Background 92
Figure 5.2: Company 5: Structure Details 92
Figure 5.3: Company 5: Structure 93
Figure 5.4: Company 5: Department Staffing 94
Figure 5.5: Company 5: Pharmacoeconomics/Health Outcomes Funding 95
Figure 5.6: Company 5: Brand-Level Pharmacoeconomics Spending 95
Figure 5.7: Company 5: Monetary Resource Allocation 96
Figure 5.8: Company 5: Time Resource Allocation 97
Figure 5.9: Company 5: Outsourcing 97
Figure 5.10: Company 5: Performance Rating/Top Challenges 98

COMPANY 6
Figure 6.1: Company 6: Background 102
Figure 6.2: Company 6: Structure Details 102
Figure 6.3: Company 6: Department Structure 103
Figure 6.4: Company 6: Department Staffing 104
Figure 6.5: Company 6: Budget for 2006 106
Figure 6.6: Company 6: Pharmacoeconomics/Health Outcomes Funding 106
Figure 6.7: Company 6: Brand-Level Phase-to-Phase Minimum Spending 108
Figure 6.8: Company 6: Brand-Level Phase-to-Phase Maximum Spending 108
Figure 6.9: Company 6: Outsourcing 110
Figure 6.10: Company 6: Time Resource Allocation 111
Figure 6.11: Company 6: Monetary Resource Allocation 111
Figure 6.12: Company 6: Performance Rating/Top Challenges 112

COMPANY 7
Figure 7.1: Company 7: Background 118
Figure 7.2: Company 7: Structure Details 118
Figure 7.3: Company 7: Department Staffing 119
Figure 7.4: Company 7: Global Department Structure 120
Figure 7.5: Company 7: Budget for 2006 122
Figure 7.6: Company 7: Pharmacoeconomics/Health Outcomes Funding 123
Figure 7.7: Company 7: Outsourcing 124
Figure 7.8: Company 7: Brand-Level Phase-to-Phase Minimum Spending 125
Figure 7.9: Company 7: Brand-Level Phase-to-Phase Maximum Spending 125
Figure 7.10: Company 7: Time Resource Allocation 127
Figure 7.11: Company 7: Performance Rating/Top Challenges 128

COMPANY 8
Figure 8.1: Company 8: Background 134
Figure 8.2: Company 8: Structure Details 134
Figure 8.3: Company 8: Department Staffing 135
Figure 8.4: Company 8: Global Department Structure 136
Figure 8.5: Company 8: Budget for 2006 139
Figure 8.6: Company 8: Pharmacoeconomics/Health Outcomes Funding 140
Figure 8.7: Company 8: Outsourcing 141
Figure 8.8: Company 8: Brand-Level Phase-to-Phase Minimum Spending 142
Figure 8.9: Company 8: Brand-Level Phase-to-Phase Maximum Spending 143
Figure 8.10: Company 8: Time Resource Allocation 144
Figure 8.11: Company 8: Monetary Resource Allocation 145
Figure 8.12: Company 8: Performance Rating/Top Challenges 146

CROSS-COMPANY MEASURES
Figure 9.1: Pharmacoeconomics/Health Outcomes 2006 Department Budgets 152
Figure 9.2: Pharmacoeconomics/Health Outcomes Funding 152

Budgets and Spending
Figure 9.3: Preclinical Maximum/Minimum Brand-Level Spending 153
Figure 9.4: Phase I Maximum/Minimum Brand-Level Spending 153
Figure 9.5: Phase II Maximum/Minimum Brand-Level Spending 154
Figure 9.6: Phase IIIa Maximum/Minimum Brand-Level Spending 154
Figure 9.7: Phase IIIb (Submission) Maximum/Minimum Brand-Level Spending 155
Figure 9.8: Phase IV Maximum/Minimum Brand-Level Spending 155
Figure 9.9: Average Costs of Cost-Minimization Studies 156
Figure 9.10: Average Costs of Cost Effectiveness Studies 156

Costs of Pharmacoeconomics Studies
Figure 9.11: Average Costs of Cost-Benefit Analyses 157
Figure 9.12: Average Costs of Cost-Utility Analyses 157
Figure 9.13: Average Costs of Budget impact Studies 158

Outsourcing
Figure 9.14: Percentage of Pharmacoeconomics/Health Outcomes Spend Outsourced 159
Figure 9.15: Percentage of Pharmacoeconomics/Health Outcomes Studies Outsourced  159

Staff Compensation Levels
Figure 9.16: Compensation for Pharmacoeconomics/Health Outcomes Department Heads 160
Figure 9.17: Compensation for Pharmacoeconomics/Health Outcomes Department Management Tier 1 160
Figure 9.18: Compensation for Pharmacoeconomics/Health Outcomes Department Management Tier 2 161
Figure 9.19: Compensation for Pharmacoeconomics/Health Outcomes Department Line Workers 161
Figure 9.20: Compensation increase given for 1 to 2 Years Experience 162
Figure 9.21: Compensation increase given for 2 to 3 Years Experience 162
Figure 9.22: Compensation increase given for 3 to 4 Years Experience 163
Figure 9.23: Compensation increase given for 5+ Years Experience 163